A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus

Sys Zoffmann Glud, Annette Balle Sørensen, Mindaugas Andruilus, Bruce Wang, Eisaku Kondo, Randi Jessen, Laszlo Krenacs, Eva Stelkovics, Matthias Wabl, Edgar Serfling, Alois Palmethofer, and Finn Skou Pedersen

Nuclear factor of activated T cell (NFAT) transcription factors play a central role in differentiation, activation, and elimination of lymphocytes. We here report on the finding of provirus integration into the NFATc3 locus in T-cell lymphomas induced by the murine lymphomagenic retrovirus SL3-3 and show that NFATc3 expression is repressed in these lymphomas. The provirus insertions are positioned close to the Nfatc3 promoter or a putative polyadenylated RNA (polyA) region. Furthermore, we demonstrate that NFATc3-deficient mice infected with SL3-3 develop T-cell lymphomas faster and with higher frequencies than wild-type mice or NFATc2-deficient mice. These results identify NFATc3 as a tumor suppressor for the development of murine T-cell lymphomas induced by the retrovirus SL3-3.

**Introduction**

The family of nuclear factor of activated T cell (NFAT) transcription factors comprises the 5 structurally related proteins NFATc1, c2, c3, and c4, whose activity is controlled by Ca$^{++}$ signals, and NFAT5, which is controlled by osmotic stress. All NFAT proteins contain a DNA binding domain of approximately 300 amino acids (aa), which, due to its similar conformation to the Rel domain of nuclear factor κB (NF-κB) factors, is designated as Rel similarity domain (RSD).$^{1,3}$ NFATc1 expression is inducible in lymphocytes, while NFATc2 and NFATc3 are constitutively expressed. They regulate lymphocyte development, and upon antigen receptor stimulation they control both the initiation and activation of immune responses, and antigen-induced cell death (AICD) of lymphocytes. In resting cells, NFAT proteins are highly phosphorylated and reside in the cytoplasm. Antigen receptor triggering leads to increasing intracellular concentrations of free Ca$^{++}$, which activate the Ca$^{++}$/calmodulin-dependent protein phosphatase calcineurin (CN). The activity of CN results in nuclear translocation of NFATs and activation (or repression) of numerous NFAT target genes. In T cells, NFAT transcription factors control the expression of many immunomodulatory genes including the cytokines interleukin-2 (IL-2), IL-4, IL-5, IL-13, and interferon γ (IFNγ); the surface receptors CD25 and Fas ligand (Fasl); and also genes that are involved in cell-cycle regulation.$^{1,3}$

Through the inactivation of Nfatc, genes in mice both individual and overlapping activities have been detected for the genes encoding Nfatc1, c2, or c3.$^{1,3}$ Whereas inactivation of Nfatc1 and c2 genes results in a general loss of lymphokine production,$^{4}$ T helper 2 (Th2)-type lymphokines are overexpressed in mice deficient for NFATc2$^{5}$ and are much more pronounced in mice double deficient for NFATc2 and NFATc3.$^{6}$ These results indicate that the NFAT factors NFATc1, c2, and c3 play an essential role in differentiation of naive Th cells to Th effector cells. In addition, NFATc3 is shown to control the transition of developing thymocytes from the CD4$^{+}$CD8$^{+}$ double-positive (DP) stage to the mature CD4$^{+}$CD8$^{+}$ or CD4$^{+}$CD8$^{+}$ single-positive (SP) stages.$^{7}$ Mice lacking NFATc3 show an impaired development of CD4 and CD8 SP thymocytes, and the resulting thymic defect is characterized by increased apoptosis of DP thymocytes.$^{7}$

Retrovirus insertion mutagenesis in mouse models has helped to identify a variety of genetic loci that are directly or indirectly contributing to the processes of tumor induction and progression.$^{8}$ The data obtained from various retroviral insertion tagging studies (http://rtcgd.ncifcrf.gov/index.html) as well as our own results include several cases of retroviral integrations within the Nfatc1 and Nfat5 loci, suggesting that deregulation of these NFAT proteins may contribute to retrovirus-induced cancerogenesis.

Using a model of T-cell lymphoma induction by the T-cell lymphomagenic retrovirus SL3-3, in combination with paternal ENU (N-ethyl-N-nitrosourea) mutagenesis, we here report the finding of 3 provirus insertions into the Nfatc3 locus, located within the Nfatc3 promoter and close to a putative proximal polyadenylated RNA (polyA) region. In all 3 cases, virus insertion resulted in a repression of NFATc3 expression. To address the effect of NFATc3 expression in lymphomagenesis, we infected wild-type mice and...
mice deficient for NFATc3 (or NFATc2) with SL3-3 and investigated the generation of retrovirolytically induced tumors and mortality. We found that NFATc3, but not NFATc2, exerts a repressive effect on both incidence and latency periods of tumor induction. This indicates a tumor suppressor role of NFATc3 for the generation of T-cell lymphomas induced by the retrovirus SL3-3.

Materials and methods

Screening for SL3-3 insertions

A large panel of T-cell lymphomas induced by the NB-tropic SL3-3 murine leukemia virus (MLV) in wild-type BALB/c mice was analyzed for provirus integration sites by anchored polymerase chain reaction (PCR).10 Virus-infected mice were offspring from crossing mice treated with ENU (doses, 3 × 20 mg/kg or 3 × 100 mg/kg body weight) with nonintertreated females. ENU is a chemical germ-line mutagen, which, in combination with insertional mutagenesis from infectious retroviruses, potentially increases the chances of detecting tumor suppressor genes by retroviral tagging.11 In 3 tumors from 3 different mice, provirus insertions at the following positions in the Nfatc3 locus (NM_010901) were found: 5’-ATATAATTTC-3AATTCTCCTCCTCTCAACCTGATGGGAGACTATCTCTGAGACGGGAGGTGGTCACTG-3’ (chromosome [Chr] 8 105372569); 5’-GGAGAAGGTTGTCACTGGTCTTCCAATCTCTCTTATATGCGGT-3’ (Chr 8 105372946); and 5’-provirus-GTTTGTGTTTTTCTTTTTGAGACGGGGAAGGGCTACTCTCTATGGCC-3’ (Chr 8 105419363). (The first 50 bases of genomic sequence that follow immediately after the virus 5’- long terminal repeat [LTR] are given. The base marked in bold is the first base after the virus 5’ LTR; that is, the given chromosome position. See also Figure 1A.)

Mice

Offspring from an initial breeding setup with crosses of Nfatc2–/–Nfatc3–/– as well as crosses of Nfatc2–/–Nfatc3+/– males with female wild-type BALB/c mice were used for further breeding. One-hundred and seventy-four newborn (< 36 hours old) BALB/c mice were inoculated intraperitoneally with wild-type NB-tropic SL3-3 MLV particles (described in Thomas et al13 and kindly provided by Christopher Y. Thomas), with an additional 70 newborn BALB/c control mice mock-injected with complete medium. At the time of weaning, tail clips were used for genotyping. The mice were monitored every day for a period of 250 days for signs of disease development (weight loss, breathing difficulties, briskly fur, inactivity, or tumor development; diagnosed on the basis of gross appearance of lymphoid organs). When sickness was registered, the mice were killed by cervical dislocation. Spleen, thymus, liver, and lymph nodes were dissected and measured, and samples were immediately frozen at −80°C. Samples from a representative number of mice from each genotypic group were analyzed by flow cytometry. Mouse breeding and housing was performed at Pipevine Biotech, Denmark.

Tumors

Tumors were diagnosed on the basis of enlargement of lymphoid organs. Based on the size of thymus and spleen in 7 healthy, mock-infected, age-matched mice and on previously used guidelines in SL3-3 studies,14 the following measures were used to consider the lymphoid organs that were enlarged and tumor bearing: spleen, 30 mm or longer; mesenteric lymph node, 20 mm or longer; and thymus and lymph nodes other than mesenteric, 10 mm or wider/longer.

Flow cytometry

Single cells from minced tissues were washed with RPMI medium (Gibco, Invitrogen, Taastrup, Denmark), and erythrocytes were lysed by incubating in 0.16 M NH4Cl, 1 mM NaHCO3, and 0.12 mM EDTA (ethylenediaminetetraacetic acid) on ice for 5 minutes and then adding 1 volume of 0.12 M NaCl, 17 mM Na-citrate. Per sample, 1 × 106 trypan blue excluding cells were incubated with anti–mouse CD16/CD32 (FcγRII receptor, Mouse Fe block; BD Pharmingen, Bröndby, Denmark) and then with antibodies (BD Pharmingen) staining T cells (CD3–phycoerythrin [PE], CD4–fluorescein isothiocyanate [FITC], CD8–peridinin chlorophyll-a protein [PerCP]–cyanine 5.5 [Cy5.5]), B cells (B220-PerCP), or myeloid cells (CD11b-FITC), or immunoglobulin (Ig) isotype controls. Appropriate isotype controls were done in parallel. Flow cytometry was performed on a fluorescence-activated cell sorter (FACS) Calsib apparatus (BD Bioscience, San Jose, CA) with a single 15-mW air-cooled Argon laser tuned at 488 nm. Data analysis, including compensation of overlapping spectra of the antibodies, was performed by use of WinList 3D (version 5.0; Verity Software House, Topsham, ME).

Tissue processing and immunohistochemistry

Paraffin sections were cut and stained either for hematoxylin and eosin (H&E) or were used for immunohistochemical staining, following wet heat-induced antigen retrieval. B-cell–, T-cell–, and myeloid cell–associated antigens were detected using monoclonal antibodies and polyclonal rabbit antibodies cross-reactive with mouse, including monoclonal anti-CD79a (Labvision, Fremont, CA) and anti–TIA-1/GMP-17 (granule associated antigens were detected using monoclonal antibodies and polyclonal rabbit antibodies cross-reactive with mouse, including monoclonal anti-CD79a (Labvision, Fremont, CA) and anti–TIA-1/GMP-17 (granule membrane protein of 17 kDa) (Immunotech, Miami, FL) as well as polyclonal anti–terminal deoxynucleotidyl transferase (TdT; DaKoCytomation, Carpinteria, CA), antitymoperoxidase (Labvision), anti-CD5e, and biotinylated anti–mouse IgM (DaKoCytomation).

**Figure 1.** Insertion of retrovirus SL3-3 in the Nfatc3 locus represses NFATc3 expression. (A) Schematic representation of Nfatc3 with SL3-3 MLV insertion sites and orientations indicated by arrowheads (>). The numbers adjacent to the proviruses denote the distance (in bp) between provirus insertions and the upstream and downstream exons or the distance between neighboring insertions. TAD indicates transcriptional domain; NLS, nuclear localization signal; a, calcineurin binding site; b, region within the regulatory domain (RD) containing multiple phosphorylation sites; c, the DNA-binding motif in the DNA-binding domain (DBD); TAD/NES, combinatorial C-terminal TAD (TAD-C) and nuclear export signal found in NFATc1 and NFATc3; _, the alternative 33-aa sequence of the NFATx2 isoform of NFATc312 lacking TAD-C motif; †, the 30-aa deletion of an inactive isoform of NFATc3‡; and *, location of a putative polyA site (AATAAATAGTCTTTTTT) in Nfatc3 with start at position chr8:105418773. (B) Western blot analysis of protein extracts from lymphomas with SL3-3 insertion within the Nfatc3 locus using polyclonal anti-NFATc1 or anti-NFATc3 antibody for staining (“Materials and methods”). Protein extracts from normal thymus of a wild-type mouse (lane 1) are compared with lysates from tumors of Nfatc3–/– (lane 2) or wild-type mice without (lane 3) and with (lanes 4 and 5, representing tumors with insertion in intron 8 and at 1.6-kb upstream, respectively) SL3-3 MLV insertion at the Nfatc3 locus. (C) RNA expression of NFAT genes in SL3-3–induced tumors as determined by semiquantitative RT-PCR. Shown are the expression in normal thymus, thymic tumors derived from wild-type, Nfatc2–/–, and Nfatc3–/– mice, and thymic tumors with provirus insertion in Nfatc3 locus (at intron 8 and 1.6-kb upstream). cDNA amounts were equalized to β-actin signals. WT indicates wild type.
Acetoxy-fixed frozen tumor sections were incubated with a mixture of Alexa-488–conjugated anti–mouse CD4, Alexa-647–conjugated anti–mouse CD8 (both from Caltag, Burlingame, CA), and biotinylated anti–CD3, followed by incubation with streptavidine-Cy3 (both from BD Pharmingen). Finally, nuclei were stained with DAPI (4,6-diamidino-2-phenylindole; Sigma, St Louis, MO). Immunofluorescent signals were captured using confocal laser scanning microscopy (software version 2.5; Leica, Heidelberg, Germany).

RT-PCR

Semiquantitative reverse-transcriptase (RT)–PCR was performed using RNA extract from normal thymus and thymic tumors. Total RNA (3 μg) was reverse transcribed using RevertAid H Minus First Strand cDNA Syntheses Kit (Fermentas, Hanover, MD). Standard PCR was done using 150 ng or 6 ng RNA equivalent of cDNA for NFATc3 and β-actin, respectively, for 25 cycles. For NFATc1, touchdown PCR was done for 20 cycles followed by standard PCR for 20 cycles. For NFATc2, touchdown PCR was done for 14 cycles followed by standard PCR for 30 cycles. Primers used for detecting Nfatc1, Nfatc2, Nfatc3, and β-actin are as follows: nfatc1s, 5′-gtcctgaacgcattcgccttc-3′; nfatc1as, 5′-ggcggctgcagcagctctca-3′; nfatc2s, 5′-catacggcggccagacacagcgg-3′; nfatc3as, 5′-ccctcttctctgatgtaattgcag-3′; nfatc3s, 5′-ccactgtggtccattgtaactgg-3′; nfatc3as, 5′-tctcgagaagaactcagagc-3′; β-actins, 5′-tcaacccagcagctacgtgactcctc-3′; and β-actins, 5′-ttagagacgctacctgtg-3′.

Western blotting

For detecting NFATc1 or NFATc3, 30 μg protein per lane was electrophoresed through 8% polyacrylamide (PAA) gels and immunodetected with polyclonal anti–NFATc1 and anti–NFATc3 antibody (sc-8321; Santa Cruz Biotechnology, Santa Cruz, CA) followed by visualization using the enhanced chemiluminescence (ECL) system (Amer sham, Arlington Heights, IL). To confirm equal protein loading, membranes were stripped and subsequently incubated with an anti–β-actin antibody (sc-8432; Santa Cruz).

Results

Extinction of NFATc3 expression by proviral insertion in T-cell lymphomas

In a large-scale study of retroviral tagging in SL3-3–induced T-cell lymphomas of 1767 mice, we found 3 specific provirus insertions in the Nfatc3 gene in 3 independent tumors, out of a total of 6514 mapped provirus tags from all the tumors. Two of the insertion sites in Nfatc3 are located within the 5′ promoter region at positions 1.3 kb and 1.6 kb upstream of exon 1. The third provirus integration site is positioned in intron 8, that is, 1063 base pairs (bp) and 1.6 kb upstream of exon 1. The latencies of tumor development in mice with provirus insertion in the Nfatc3 gene (81, 85, and 98 days) were similar to those of the complete study group (84 ± 30 days).

To investigate the effects of provirus insertions on NFATc3 expression, we performed Western blots using protein extracts from tumors harboring insertions in the Nfatc3 gene locus. In these assays, we found no detectable NFATc3 protein expression (Figure 1B). The repression of protein expression, however, showed by semiquantitative RT-PCR not to be paralleled by a similar repression of Nfatc3 mRNA expression (Figure 1C). Likewise, the expression of the genes Nfat2 and Nfat1 as well as NFATc1 protein was not affected by the presence NFATc3 repression in the tumors (Figure 1B-C). The tumor with provirus insertion 1.3-kb upstream of Nfatc3 demonstrated low-quality RNA (presumably because it was not retrieved immediately after death) and was therefore left out of the RT-PCR assay and the Western blot. The repression of NFATc3 expression in the tumors led us to assume that NFATc3 may act as a tumor suppressor for the SL3-3–induced lymphomagenesis and prompted us to study lymphomagenesis in NFATc3-deficient mice.

Enhanced disease incidence and shorter latency in NFATc3-deficient mice

To study the role of NFATc3 and of the related NFATc2 in oncogenesis, new born BALB/c mice, as well as BALB/c mice homozygous or heterozygous for inactivated Nfatc2 or Nfatc3 genes, were inoculated intraperitoneally with the T-cell lymphogenic retrovirus SL3-3 MLV. Disease incidence and latency periods were monitored for an observation period of 250 days. Since no major differences with regard to disease incidence, tumor phenotype, and latency were observed for animals with homozygous deletion of either Nfatc2 or Nfatc3 harboring 1 or 2 wild-type alleles of the complementary Nfat gene, 3 groups of animals were compared: Nfatc22/2, Nfatc32/2, and those with wild-type Nfatc2 and c3 genes (including double heterozygotes, Nfatc22/c32/2). Nfatc22/c23/2 mice remained unconsidered due to the severe phenotype they develop, as described previously.17

Table 1. Disease and lymphoma development in SL3-3—infected BALB/c mice

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Virus</th>
<th>Disease incidence, % (no./total)</th>
<th>Lymphoma incidence, % (no./total)</th>
<th>Mean latency, d ± std†</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>SL3-3</td>
<td>80 (8/10)</td>
<td>70 (7/10)</td>
<td>88 ± 32</td>
</tr>
<tr>
<td>Nfatc22/c32/2</td>
<td>SL3-3</td>
<td>83 (40/48)</td>
<td>65 (31/48)</td>
<td>93 ± 45</td>
</tr>
<tr>
<td>Nfatc22/c32/2</td>
<td>SL3-3</td>
<td>100 (6/6)</td>
<td>100 (6/6)</td>
<td>80 ± 8</td>
</tr>
<tr>
<td>Nfatc22/c32/2</td>
<td>SL3-3</td>
<td>100 (10/10)</td>
<td>80 (8/10)</td>
<td>83 ± 23</td>
</tr>
<tr>
<td>Nfatc22/c32/2</td>
<td>SL3-3</td>
<td>93 (38/41)</td>
<td>63 (26/41)</td>
<td>108 ± 51</td>
</tr>
<tr>
<td>Nfatc22/c32/2</td>
<td>SL3-3</td>
<td>89 (42/47)</td>
<td>60 (28/47)</td>
<td>110 ± 43</td>
</tr>
<tr>
<td>Pooled genotypes</td>
<td>WT</td>
<td>SL3-3</td>
<td>83 (48/58)</td>
<td>66 (38/58)</td>
</tr>
<tr>
<td>Pooled genotypes</td>
<td>WT</td>
<td>SL3-3</td>
<td>19 (4/21)</td>
<td>10 (2/21)</td>
</tr>
<tr>
<td>Pooled genotypes</td>
<td>Nfatc22/2</td>
<td>SL3-3</td>
<td>100 (16/16)</td>
<td>88 (14/16)</td>
</tr>
<tr>
<td>Pooled genotypes</td>
<td>Nfatc22/2</td>
<td>Mock</td>
<td>10 (1/10)</td>
<td>0 (0/10)</td>
</tr>
<tr>
<td>Pooled genotypes</td>
<td>Nfatc22/2</td>
<td>SL3-3</td>
<td>91 (80/88)</td>
<td>60 (53/88)</td>
</tr>
<tr>
<td>Pooled genotypes</td>
<td>Nfatc22/2</td>
<td>Mock</td>
<td>61 (11/18)</td>
<td>17 (3/18)</td>
</tr>
</tbody>
</table>

Std indicates standard deviation.

*Based on clear enlargement of lymphoid organs as described in “Materials and methods.”

†Mean latency is calculated for disease-developing mice.

‡Only one mouse in the group developed disease; number indicates its lifespan.
mice (P = .85), which is also reflected in the survival curves for the 2 groups (Figure 2A). Among mock-infected control mice, only those with inactivated \( \text{Nfatc2} \) gene showed a considerable number of disease-developing mice (11 of 18), of which 3 presented with significantly enlarged organs, an observation consistent with the previously published phenotype.18

Focusing only at clear enlargement of lymphoid organs, lymphoma incidence was lower than disease incidence in all pooled genotype groups. Lymphoma incidence was markedly higher among \( \text{Nfatc3}^{+/+} \) mice, with 14 (88%) of 16 mice showing significantly enlarged organs in comparison with wild-type and \( \text{Nfatc2}^{+/+} \) mice having lymphoma incidences of 66% and 60%, respectively (Table 1; Figure 2B).

The finding that mice bearing homozygous inactivation of the \( \text{Nfatc3} \) gene have a shorter latency for SL3-3–induced T-cell lymphoma than those with either defective \( \text{Nfatc2} \) gene or wild-type \( \text{Nfat} \) genes supports the notion that NFATc3, but not NFATc2, exerts a tumor-suppressor function for SL3-3–induced tumors.

To address if the loss of NFATc3 (or of NFATc2) had any influence on disease specificity, the tumors were examined by staining sections with H&E, or with various antibodies raised against extracellular or intracellular markers. A typical feature of the tumors, irrespective of the tumor tissue or \( \text{Nfat} \) genotype, is, as shown in Figure 3A, a lymphomateous infiltrate composed of medium-sized monotonous tumor cells with prominent mitotic activity. The cells display rather dispersed chromatin structure and relatively low nuclear-cytoplasm ratio, suggesting that the tumor cells are of an early differentiation state. Most of the cases analyzed revealed a strong membranous immunostaining for CD3\( \text{a} \) and no staining for myeloperoxidase (MPO, some positive signal due to the presence of body macrophages, Figure 3A), TIA-1, CD79a, and IgM (data not shown), indicating that the tumor cells are of T-cell or NK-cell origin. Several cases revealed TdT-positive tumor cells (Figure 3A), which adds further evidence to a precursor T-cell origin of the tumors.19 Additional phenotypic characterization of the differentiation state of the T cells revealed different tumor

---

**Figure 2.** Diminished survival and increased tumor incidence in \( \text{Nfatc3}^{+/+} \) mice after SL3-3 infection. (A) Survival curves of \( \text{Nfatc3}^{+/+} \) (n = 16/16), \( \text{Nfatc2}^{+/+} \) (n = 80/88), or wild-type (n = 48/58) (including heterozygotes) BALB/c mice infected with SL3-3. (B) The cumulative incidence of tumor development of \( \text{Nfatc3}^{+/+} \) (n = 14/16), \( \text{Nfatc2}^{+/+} \) (n = 53/88), and wild-type (n = 38/58) mice based on enlarged lymphoid organs as defined previously (for details, see “Materials and methods”).

**Figure 3.** Immunohistochemical analyses of SL3-3–induced tumors. (A) Sections of a representative tumor of the thymus stained with either H&E or antibodies against CD3\( \text{a} \), TdT, and myeloperoxidase (MPO). (B) Immunohistochemical stainings of CD3\( \text{a} \) tumors from different animals for double fluorescent analysis of CD4 and CD8 expression. All of the samples shown were either CD3\( \text{a} \) bright (nos. 160, 163, 407 all thymus) or CD3\( \text{a} \) dim (no. 275; mesentery lymph node). The genotypes of the mice with the tumors shown are \( \text{Nfatc3}^{+/+} \) (nos. 160, 163, 407) and \( \text{Nfatc2}^{+/+} \) (no. 275). Images were acquired with Leica TCS SP2 Confocal System equipped with a Leica DMRE microscope with an HCX PL APO 40×/1.25 NA oil CS objective lens. Images were processed with Leica Confocal Software version 2.61 (all from Leica Microsystems, Mannheim, Germany).
genic thymuses and spleens of virus-infected mice had up to 15% type (Figure 4D), probably reflecting oligoclonal tumors. Among Two dominant phenotypic cell

Table 2. Lymphoma phenotypes induced upon SL3-3 MLV infection

<table>
<thead>
<tr>
<th>Phenotype Total</th>
<th>WT</th>
<th>Nfatc2−/−</th>
<th>Nfatc3−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>One dominant phenotypic cell population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immature CD4⁺CD8⁻ DN</td>
<td>38</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Immature CD4⁺CD8⁺ DP</td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Mature CD4⁺CD8⁻ SP</td>
<td>17</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Mature CD4⁺CD8⁺ SP</td>
<td>8</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Two dominant phenotypic cell populations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4⁺CD8⁻ DP / CD4⁺CD8⁺ SP</td>
<td>11</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>CD4⁺CD8⁺ DP / CD4⁺CD8⁺ SP</td>
<td>11</td>
<td>9</td>
<td>3</td>
</tr>
</tbody>
</table>

NA indicates not applicable.
*Nine of these 38 tumors were analyzed by immunohistochemistry.
†Two of these 11 tumors were analyzed by immunohistochemistry.

Figure 4. SL3-3 infection leads to various subtypes of T-cell lymphomas in wild-type and Nfatc2−/− or Nfatc3−/− deficient mice. Flow cytometry analysis of cells from (A) spleen of mock-infected Nfatc2−/− mouse, (B) spleen lymphoma from a SL3-3–infected Nfatc2−/− mouse, (C) thymus lymphoma from an SL3-3–infected wild-type mouse, and (D) spleen lymphoma from an SL3-3–infected Nfatc3−/− mouse. (A-B) To distinguish between T cells, myeloid cells, and B cells, cells were stained with a mixture of anti-CD3–PE, anti-CD11b–FITC, and anti-CD45/B220–PerCP Abs, respectively. In panels C and D, a mixture of anti-CD3–PE, anti-CD4–FITC, and anti-CD8–PerCP–Cy5.5 antibodies was used to distinguish among T-cell subsets. Two different populations of T cells in panel D are indicated with rectangles 1 and 2 representing CD3⁺CD4⁺CD8⁻ cells and CD3⁺CD4⁻CD8⁺(dim)CD69⁺ SP T-cell subsets, respectively. Note that parallel analysis of both thymus and spleen tumors derived from the same animal revealed basically identical FACSC profiles in most of the cases investigated. Five percent probability contour plots are shown. Grids are positioned according to background fluorescence of isotype controls. Numbers in quadrants indicate the percentage of cells within the limits of the quadrants. For a summary of tumor phenotypes, see Table 2.

Discussion

Retroviral insertional mutagenesis in laboratory mice provides a powerful tool to identify cancer-relevant genes. As a result of infecting mice that either express proto-oncogenic transgenes or harbor homozygous deletions of particular genes, the relevance of partially redundant gene products with regard to cancerogenesis can be further defined.20,21 Here, we report on insertions of T-cell lymphomagenic retrovirus SL3-3 MLV into the Nfatc3 locus as a common insertion site (CIS) and indicates the presence of a cancer-associated gene.20 Furthermore, we show that these insertions are associated with repression of NFATc3 protein level, while the Nfatc3 RNA level is similar to
normal thymus and control tumors. In these tumors, only one allele of the Nfatc3 gene is targeted by the provirus. Hence, the lack of protein must involve posttranscriptional mechanisms. We cannot, however, exclude an additional transcriptional repression effect at either the provirus-targeted or untreated, possibly ENU-mutated, allele. Irrespective of the mechanisms, the association of provirus insertion with repression of the NFATc3 protein level in the 3 tumors suggests that abrogation of NFATc3 expression provides the cell with a survival and/or proliferation advantage.

In addition to the Nfatc3 insertions, the 3 tumors also contained provirus insertions into other noncommon retroviral insertion sites as well as insertions at the frequently targeted oncogenes Myc and Myb. How NFATc3 protein repression may cooperate with these other insertional mutations in lymphomagenesis must await further studies.

The provirus insertions in Nfatc3 are positioned at comparable sites of provirus insertions found in Nfatc1 (Mouse Retrovirus Tagged Cancer Gene Database and data not shown). In either Nfatc locus, the provirus insertions cluster in or close to the promoter region, implicating an important functional role of viral insertions in regulation of NFAT expression. Likewise, the insertions near the 3′ end of both genes appear to cluster at or near polyA addition sites. This is true for the Nfatc1 gene where several insertions were found in intron 10 (Mouse Retrovirus Tagged Cancer Gene Database and data not shown), that is, within the last intron, located just 5′ from the short exon 11, which harbors the strong distal polyA site. The 3′ insertion next to exon 8 in Nfatc3 (Figure 1A) seems to be located near a putative proximal polyA site. This conclusion is supported by the generation of short NFATc3 isoforms (designated as NFATc4a and NFATc4b by Hoey et al), which are similar in length to NFATc1/A. Short NFATc1 isoform is synthesized by the use of a proximal, inducible polyA site, which has been described to terminate exon 9 of Nfatc1 gene (which is homologous to exon 8 of Nfatc3).

Comparing SL3-3 MLV–induced lymphomagenesis in wild-type, Nfatc2−/−, and Nfatc3−/− BALB/c mice, we obtained support for a tumor-suppressor function of NFATc3. Virus-infected NFATc3-deficient mice develop lymphomas with a significantly shorter latency period and at a much higher frequency than both wild-type and NFATc2-deficient mice. The tumor phenotypes induced, however, did not differ among the different Nfatc2/3 genotypes. Phenotypically, a major proportion of tumors were found to be derived from immature CD4−CD8− DN or CD4+CD8+ DP thymocytes. This finding is consistent with previous studies of SL3-3–accelerated lymphomas in AKR mice. In contrast, inbred NMRI mice primarily develop lymphomas of the mature CD3+CD4+CD8+ SP T-helper cell phenotype upon infection with SL3-3.

It was interesting to note that SL3-3–infected Nfatc2−/− mice are markedly less prone to lymphoma induction compared with Nfatc3−/− mice. Part of the explanation for this difference might be due to the different importance of NFATc2 and NFATc3 in thymocytes. During thymocyte development, NFAT members are expressed at varying levels and NFATc3 is most abundantly expressed at the CD4+CD8− DP stage of thymocyte differentiation. A constitutively active form of NFATc3 was recently shown to induce the differentiation of CD4+CD8+ DP lymphocytes to mature SP T cells, whereas other NFAT proteins appear to be more important in maturation of peripheral lymphocytes. Mice lacking NFATc3 show an impaired development of CD4+ and CD8+ thymocytes and peripheral T cells. In addition, the thymic defect is characterized by increased apoptosis of CD4+CD8− DP thymocytes. Similar to NFATc2, NFATc3 acts in a prosurvival manner in peripheral T cells, whereas in thymus, NFATc3 appears to promote the survival of thymocytes by regulating Bcl-2 and Fasl expression. Earlier studies suggest that initial SL3-3 virus infection and cell transformation evolve in the immature thymocytes and induce thymic atrophy. Hence, the higher lethality of CD4−CD8− DP thymocytes in Nfatc3−/− mice may increase the chances of the virus to induce thymic atrophy, providing space for the expansion of truly malignant cells escaping the normal selection process in thymus. In part, this may explain the higher risk of lymphoma development in Nfatc3−/− mice compared with wild-type and Nfatc2−/− mice. Nevertheless, the loss of NFATc3 expression by provirus tagging, in the 3 SL3-3–induced tumors, demonstrates that loss of function of NFATc3 also at the level of a single-cell clone can provide an infected cell with a selective advantage in provirus-induced transformation.

Until now, a direct involvement of NFAT factors in lymphomagenesis has not been demonstrated. Due to aberrant chondrocyte development in NFATc2-deficient mice, NFATc2 was suggested to represent a tumor suppressor for the development of cartilaginous tumors, whereas a constitutively active version of NFATc1/A behaves like an oncprotein by inducing a transformed phenotype upon ectopic expression in 3T3-L1 fibroblasts. Our results presented here and the prosurvival activity of several NFAT proteins, including NFATc2 and c, suggest that several NFAT proteins can act as tumor suppressors for the development of lymphoid tumors in mice. It remains to be shown whether this might also hold true for human tumors.

A large study of gene expression profiles from human B-cell lymphomas included expression analysis of both NFATc1 and NFATc3. By searching the online supplementary Lymphoma/Leukemia Molecular Profiling Project (LLMP) microarray datasets, we did not detect remarkable changes in expression levels of NFATc3 in numerous samples from patients with lymphoma. In contrast, NFATc1 expression was found to be low or mildly expressed in follicular B-cell lymphoma, reduced in chronic lymphocytic lymphoma (B-CLL), and markedly reduced in several transformed lymphoma cell lines. In the majority of diffuse large B-cell lymphomas (DLBCLs), NFATc1 expression was reduced or low (except for 3 samples in which expression was as high as in normal T cells). Our own histochemical stainings of a large panel of human lymphomas demonstrate that in human anaplastic large cell lymphomas (ALCLs) and in classic Hodgkin lymphomas NFATc1 expression is suppressed, in most cases due to the epigenetic silencing of Nfatc1 promoter region by DNA methylation (A. Akimzhanov, L.K., S. Klein-Hessling, E. Stelkovics, E. Bagdi, E.K., T. Schlegel, S. Chupvilo, T. Rüdiger, H. K. Müller-Hermelink, A.P., and E. Serfling, manuscript submitted). These findings suggest that similar to the related NF-κB proteins, NFAT proteins control the development and progression of various types of human lymphomas and, possibly, of other tumors, and therefore, exert both oncogenic and tumor-suppressive activities depending on the specific cellular context.

Acknowledgments

We wish to thank Petra Sprosty and Julia Burghardt for excellent technical assistance; Dr Laurie Glimcher (Boston) for kindly providing mice with inactivated Nfatc2 and Nfatc3 alleles; and Alexander Schmitz for help with flow cytometry analysis.


A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus

Sys Zoffmann Glud, Annette Balle Sørensen, Mindaugas Andrulis, Bruce Wang, Eisaku Kondo, Randi Jessen, Laszlo Krenacs, Eva Stelkovics, Matthias Wabl, Edgar Serfling, Alois Palmetshofer and Finn Skou Pedersen

Updated information and services can be found at:
http://www.bloodjournal.org/content/106/10/3546.full.html

Articles on similar topics can be found in the following Blood collections
- Neoplasia (4182 articles)
- Oncogenes and Tumor Suppressors (795 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml